Worcester, MANCT06017622Now EnrollingIRB Ready

Acute Cannabis-induced CNS Depression Clinical Trial in Worcester, MA

Access cutting-edge acute cannabis-induced cns depression treatment through this clinical trial at a research site in Worcester. Study-provided care at no cost to qualified participants.

Sponsored by Anebulo Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Worcester location

Preparing your pre-screening questions…

Expert Care in Worcester

Access acute cannabis-induced cns depression specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute cannabis-induced cns depression treatment provided free

Apply for This Worcester Location

Check if you qualify for this acute cannabis-induced cns depression clinical trial in Worcester, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Worcester

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Worcester site if eligible
  4. 4Begin participation

About This Acute Cannabis-induced CNS Depression Study in Worcester

This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to acute cannabis-induced CNS depression.

Sponsor: Anebulo Pharmaceuticals

Who Can Participate

Inclusion Criteria

The patient visits the ED with signs and symptoms of suspected acute cannabis-induced CNS depression, as evidenced by the patient suffering from clinically significant CNS depression combined with the following criteria: a) Exposure to cannabis or cannabis-derived products, or other products containing any CB1 agonist (such as Δ8-THC, HHC) within the last 12 hours, confirmed through one or more of the following: i. Positive toxicology testing, or ii. Other clinical evidence, such as reliable collateral history (e.g., from caregivers, EMS personnel, or witnesses), physical evidence (e.g., product packaging), or a consistent self-report. AND EITHER b) Symptoms are associated with cannabis exposure and developed during, or shortly after, cannabis exposure; OR c) In the judgment of investigator or designated clinician, the presentation includes symptoms consistent with acute cannabis-induced CNS depression (e.g. respiratory rate depression, increased sedative effects).
Blood samples are taken as part of routine clinical procedures, or the patient has an IV line through which blood can be taken.
The LAR is willing and able to provide consent.
The patient is willing and able to provide assent, if applicable and feasible, based on age and clinical condition.

Exclusion Criteria

A potential patient who meets any of the following criteria will be excluded from participation in this study:
Anything that, in the opinion of the PI, would place the patient at increased risk or preclude the patient's compliance with or completion of the study.
Patient is presenting with signs or symptoms that are better explained by another medical condition or mental disorder, exposure to a drug other than cannabis, and, at the PI's discretion, are not induced by acute cannabis exposure.
Patient presenting with cannabis use disorder (CUD), cannabis hyperemesis syndrome (CHS) or cannabis withdrawal syndrome (CWS)
Patients who are brought in by law enforcement, i.e., cannabis intoxication associated with a vehicle accident (driving under the influence).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Worcester?

Yes, this clinical trial (NCT06017622) has an active research site in Worcester, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Cannabis-induced CNS Depression Treatment Options in Worcester, MA

If you're searching for acute cannabis-induced cns depression treatment options in Worcester, MA, this clinical trial (NCT06017622) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Worcester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute cannabis-induced cns depression specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute cannabis-induced cns depression clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Worcester, MA

See all depression clinical trials recruiting in Worcester — not just this study.

Browse Depression Trials in Worcester →

Browse More Trials by Condition

Depression TrialsUlcerative Colitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Worcester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Worcester, MA